Utilize este identificador para referenciar este registo:
http://hdl.handle.net/10362/143638| Título: | Local Breast Microbiota |
| Autor: | Vitorino, Marina Alpuim Costa, Diogo Vicente, Rodrigo Caleça, Telma Santos, Catarina |
| Palavras-chave: | breast cancer cancer immune microenvironment immune system immunotherapy microbiome microbiota treatment Oncology Cancer Research SDG 3 - Good Health and Well-being |
| Data: | Ago-2022 |
| Resumo: | The tumour microenvironment (TME) comprises a complex ecosystem of different cell types, including immune cells, cells of the vasculature and lymphatic system, cancer-associated fibroblasts, pericytes, and adipocytes. Cancer proliferation, invasion, metastasis, drug resistance and immune escape are all influenced by the dynamic interaction between cancer cells and TME. Microbes, such as bacteria, fungi, viruses, archaea and protists, found within tumour tissues, constitute the intratumour microbiota, which is tumour type-specific and distinct among patients with different clinical outcomes. Growing evidence reveals a significant relevance of local microbiota in the colon, liver, breast, lung, oral cavity and pancreas carcinogenesis. Moreover, there is a growing interest in the tumour immune microenvironment (TIME) pointed out in several cross-sectional studies on the correlation between microbiota and TME. It is now known that microorganisms have the capacity to change the density and function of anticancer and suppressive immune cells, enabling the promotion of an inflammatory environment. As immunotherapy (such as immune checkpoint inhibitors) is becoming a promising therapy using TIME as a therapeutic target, the analysis and comprehension of local microbiota and its modulating strategies can help improve cancer treatments. |
| Descrição: | Funding Information: D.A.C. has received honoraria from the Portuguese Navy, CUF Oncologia, and NTT DATA, and has served as a speaker, advisory board member, or has received research or education funding from AstraZeneca, CUF Oncologia, Daiichi Sankyo, Gilead, Hoffmann-La Roche, Merck KGaA, Merck Sharp & Dohme, Nestlé, Novartis, Pfizer, Nanobiotix, Puma Biotechnology Inc., Sanofi, Seagen Inc., and Uriage. Publisher Copyright: © 2022 by the authors. |
| Peer review: | yes |
| URI: | http://hdl.handle.net/10362/143638 |
| DOI: | https://doi.org/10.3390/cancers14153811 |
| ISSN: | 2072-6694 |
| Aparece nas colecções: | NMS - Artigos em revista internacional com arbitragem científica |
Ficheiros deste registo:
| Ficheiro | Descrição | Tamanho | Formato | |
|---|---|---|---|---|
| cancers_14_03811_v2.pdf | 934,81 kB | Adobe PDF | Ver/Abrir |
Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.











